Seer’s Board Keeps Saying No — But the Real Question Is Whether $2.40 Is an Insult or an Intervention

Picture the Seer board room on the morning of May 21, 2026. The Radoff-JEC Group — Bradley L. Radoff and Michael Torok, holding approximately 7.8% of Seer’s outstanding shares — has just lobbed its third unsolicited, non-binding proposal across the table: $2.40 per share in cash, plus a contingent value right. The board looks at the number, deliberates, and does what it has done twice before. It says no — unanimously. Three proposals. Three rejections. And a proxy contest still burning in the background.

What looks like a boardroom standoff is actually a live demonstration of one of biotech’s most uncomfortable structural problems: the gap between what a platform company believes it is worth and what a capital market, exhausted by years of proteomics hype, is willing to pay today. That gap, in Seer’s case, is not a rounding error. It is an existential argument about the commercial destiny of a technology that has not yet crossed the threshold from scientific credibility to revenue scale.

The Radoff-JEC Group’s $2.40 offer frames the debate in its starkest terms. For context, Thermo Fisher acquired Olink Holding AB for approximately $3.1 billion — a deal that set the high-water mark for proteomics platform valuations and instantly became the comparator every board in the sector reaches for when an activist shows up with a lowball term sheet. Seer’s board is almost certainly citing Olink in its rejection letters.

The Architecture of a Lowball Bid

To understand why the board keeps saying no, you have to understand what Seer actually built. Founded in 2017 and launched publicly in December 2018, Seer built its business around the Proteograph™ platform — a system designed to deliver rapid, cost-effective, broad-scale proteomic profiling with enough accuracy to detect cancer and neurological diseases before symptoms appear. CEO Omid Farokhzad, who chairs the board alongside directors including MIT’s Robert Langer and CRISPR pioneer Rachel Haurwitz, has consistently positioned Seer as infrastructure for the next generation of biomarker discovery. That is not a modest ambition, and a $2.40 per share cash offer does not honor it.

But here is the counterintuitive read that most coverage of this standoff is missing: the activists may not be wrong about the price, even if they are wrong about the timing. The contingent value right attached to the $2.40 offer is a tell. It signals that Radoff and Torok privately believe there is meaningful upside — enough that they want to capture it rather than leave it for the current shareholders. A CVR is not a concession. It is a mechanism for having it both ways: pay a floor price now, collect the ceiling later if the platform delivers. That structure usually appears when the bidder has done enough diligence to believe the asset is undervalued but wants to hedge the execution risk. The board reading this as an insult may be missing the embedded compliment.

The proxy contest running parallel to the acquisition proposals adds another layer. When activists own 7.8% of shares and are simultaneously pursuing board seats and a buyout, the standard M&A playbook breaks down. This is not a clean hostile takeover. It is a dual-track pressure campaign designed to force a strategic alternative — sell the company, restructure the board, or accelerate a partnership — before the next annual meeting resets the leverage map. Every rejected proposal is also a PR document filed with the SEC, shaping the narrative for shareholder votes that are now directly downstream of this fight.

What the Olink Precedent Actually Proves

The Thermo Fisher-Olink deal is the number every proteomics CEO has memorized, but it deserves a harder look before Seer’s board uses it as their valuation floor. Olink sold for $3.1 billion — but Olink had already built a commercially validated proximity extension assay platform with pharmaceutical and academic customers across multiple continents, a recurring revenue base, and established relationships with drug developers running large-scale biomarker programs. Thermo Fisher paid a strategic premium for a business that was already scaling, not one that was still demonstrating platform utility.

Seer’s Proteograph occupies a different commercial moment. The platform’s scientific promise — pre-symptomatic cancer and neurological disease detection at population scale — is real, and the board’s scientific advisory bench, anchored by Robert Langer, gives it genuine credibility. But scientific credibility and commercial scalability are different variables, and public markets, burned repeatedly by diagnostics platforms that could not convert academic enthusiasm into hospital system contracts, have largely stopped paying for the former while waiting for the latter. That dynamic is precisely why a group holding 7.8% of the shares is making a cash offer rather than simply waiting for the stock to recover.

The deeper pattern here cuts across the entire diagnostics innovator space. When a platform company’s market capitalization drifts low enough that activists can propose an acquisition at what feels like a discount — and the board’s strongest rebuttal is a reference to a deal done for a different company at a different stage — the board has already lost part of the argument. The correct response to a persistent lowball activist is not three consecutive rejections. It is a credible, specific, near-term demonstration that the standalone path creates more value than the exit. Seer’s board has not yet supplied that demonstration publicly, and every quarterly earnings cycle without a commercial inflection point is another data point the activists will put in front of shareholders.

The Endgame That Neither Side Will Name

Here is what the press releases will not say directly: both sides are positioning for a negotiated exit at a price somewhere above $2.40 and below whatever Seer’s board believes the Proteograph platform is worth at scale. The third proposal and third rejection are not endpoints — they are opening moves in a compressed timeline shaped by the proxy contest. If Radoff and Torok win even one board seat at the next annual meeting, the dynamics of any future negotiation shift materially. A director aligned with the activist bloc changes the information environment inside the boardroom and signals to potential strategic acquirers — large life science instrument companies, genomics platforms looking to add proteomics capabilities, or pharma companies building biomarker infrastructure — that the current board’s resistance has a ceiling.

Strategic acquirers are watching this. Any life science tools company with a proteomics gap in its portfolio — and there are several — now has a live data point: Seer’s board will reject $2.40, which tells you where the floor is, but the ongoing proxy pressure tells you the board’s ability to hold that floor may be time-limited. The contingent value right in the current offer is almost certainly a negotiating variable, not a fixed term. A revised structure that front-loads more cash and restructures the CVR trigger might close the gap faster than either side’s public posture suggests.

For any BD team at a strategic acquirer currently modeling a proteomics tuck-in, the calculus is specific: Seer’s Proteograph platform, positioned for pre-symptomatic oncology and neurology detection, would require years and hundreds of millions of dollars to replicate internally. The Olink precedent at $3.1 billion sets the high end of a range that assumes commercial maturity. A deal for Seer at, say, $4.00 to $5.00 per share — a number that still sits well below the per-share implied value of an Olink-equivalent outcome — might thread the needle between the activist floor and the board’s standalone ceiling. The Radoff-JEC Group just told the market that $2.40 is where serious conversation starts. The board’s three unanimous rejections just told the market it ends somewhere higher. Every sophisticated acquirer reading those two data points is now doing the same arithmetic.

The next signal to watch is not the fourth proposal. It is whether a credible third-party acquirer enters the picture before the proxy vote closes — because that arrival would immediately render the entire Radoff-JEC campaign either a catalyst that unlocked a better outcome for shareholders, or a cautionary tale about activist timelines running faster than platform companies can prove their value.

References

1. GlobeNewswire — “Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group”
2. BusinessWire — “The Radoff-JEC Group Submits its Third Non-Binding Proposal to Acquire Seer, Inc.”
3. Drug Discovery Trends — “How Seer Aims to Remove Technological Barriers to Studying the Proteome”
4. Fierce Biotech — “Thermo Fisher to Absorb Proteomics Player Olink in $3.1B Deal”
5. Seer, Inc. — Board of Directors and Leadership